Novo Nordisk A S
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Novo Nordisk A S has 3 disclosed suppliers and 3 disclosed customers in SEC filings. Named in filings as Novo Nordisk A/S (4).
—
SentenceFor example, in November 2024, we entered into a research and development collaboration and license agreement with Novo Nordisk A/S ("Novo Nordisk"), pursuant to which we granted Novo Nordisk an exclusive worldwide license to our TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases and a product-by-product exclusive license in cardiovascular diseases.
SentenceSubject to certain exceptions and limitations, Novo Nordisk reimburses us for costs and expenses we incur under the Transition Services Agreement, including third-party costs and expenses, costs associated with delivery of transition services by Omeros personnel on an hourly basis at rates specified in the Transition Services Agreement, and for our inventories of zaltenibart drug substance and product.
SentenceIn November 2019, we entered into a license agreement with Novo Nordisk A/S, or Novo Nordisk, pursuant to which Novo Nordisk granted us an exclusive
COAG S-1/Aaccession 0001193125-26-193885COAG
SentenceNovo Nordisk A/S is a shareholder and has entered into three licensing agreements with the Company for the drug candidates lirilumab, monalizumab and avdoralimab. Under the terms of the agreements, the Company will pay milestones and royalties on sales of these drug candidates.
SentenceIn February 2007, we entered into an Agreement Concerning Glucokinase Activator Project with Novo Nordisk A/S (the "Novo License Agreement") whereby we obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use, and commercialize products for the prevention, treatment, control, mitigation, or palliation of human or animal diseases or conditions.
Linked news
News
Expected move
No implied move.
Novo Nordisk A S
39.98
+0.84 · +2.15%
post 39.94 −0.10%